We also proved that the anti-SEMA4D antibody could reverse the tumor-promoting effect of SEMA4D. Our findings suggest that SEMA4D could be a new candidate prognostic biomarker as well as a potential therapeutic target for AML. Here, SEMA4D is linked to acute myeloid leukemia.